A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion;...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Haematologica
Hoofdauteurs: Lancet, Jeffrey E., Roboz, Gail J., Cripe, Larry D., Michelson, Glenn C., Fox, Judith A., Leavitt, Richard D., Chen, Tianling, Hawtin, Rachael, Craig, Adam R., Ravandi, Farhad, Maris, Michael B., Stuart, Robert K., Karp, Judith E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2015
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803139/
https://ncbi.nlm.nih.gov/pubmed/25381131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.114769
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items